Study of KITE-363 or KITE-753 in Participants With Relapsed and/or Refractory B-cell Lymphoma

Recruiting now · Phase 1/Phase 2

Conditions studied: Relapsed and/or Refractory B-cell Lymphoma

In brief

The goal of this clinical study is to learn more about the safety and effectiveness of the study drugs, KITE-363 and KITE-753, in participants with relapsed and/or refractory B-cell lymphoma.

Key facts

Study ID

NCT04989803

Run by

Kite, A Gilead Company

People needed

247

Starts

2021-10-27

Expected to finish

2030-02-01

Last updated by the study team

2026-06-29

Who can join

Age: 18 and older. Sex: any. Healthy volunteers: not accepted.

Where it is running

• Banner MD Anderson Cancer Center — Gilbert, Arizona, United States (enrolling)
• City of Hope (City of Hope National Medical Center, City of Hope Medical Center) — Duarte, California, United States (enrolling)
• Stanford Cancer Institute — Stanford, California, United States (enrolling)
• Moffitt Cancer Center — Tampa, Florida, United States (enrolling)
• Northside Hospital — Atlanta, Georgia, United States (enrolling)
• Midwestern Regional Medical Center, Inc.City of Hope Chicago — Park Ridge, Illinois, United States (enrolling)
• Norton Cancer Institute, St. Matthews Campus — Shelbyville, Kentucky, United States (enrolling)
• University of MD, Greenebaum Comprehensive Cancer Center — Baltimore, Maryland, United States (enrolling)
• Hackensack University Medical Center — Hackensack, New Jersey, United States (enrolling)
• Columbia University Irving Medical Center — New York, New York, United States (enrolling)
• University of Rochester Medical Center — Rochester, New York, United States (enrolling)
• The Ohio State University Wexner Medical Center - James Cancer Hospital — Columbus, Ohio, United States (enrolling)
• Tennessee Oncology, PLLC - Investigational Drug Services — Nashville, Tennessee, United States (enrolling)
• Vanderbilt University — Nashville, Tennessee, United States (enrolling)
• St. David's Medical Center — Austin, Texas, United States (enrolling)
• The University of Texas, MD Anderson Cancer Center — Houston, Texas, United States (enrolling)
• Virginia Oncology Associates — Norfolk, Virginia, United States (enrolling)
• Royal North Shore Hospital — St Leonards, New South Wales, Australia (enrolling)
• Concord Repatriation General Hospital — Sydney, New South Wales, Australia (enrolling)
• Royal Adelaide Hospital — Adelaide, South Australia, Australia (enrolling)
• Epworth Healthcare — East Melbourne, Victoria, Australia (enrolling)
• Jewish General Hospital — Montreal, Canada (enrolling)
• McGill University Health Center — Montreal, Canada (enrolling)
• Universitatsklinikum Wurzburg — Würzburg, Germany (enrolling)
• Academisch Medisch Centrum — Amsterdam, Netherlands (enrolling)

Full record on ClinicalTrials.gov

Trial information comes from ClinicalTrials.gov and is refreshed daily. TrialsForMe does not provide medical care and does not run the studies it lists.